One off intra-muscular bridge steroid injection was considered on starting sDMARD therapy as a bridge therapy.
Unless there was a contraindication, the patients with inflammatory PsA started their sDMARDs therapy once the diagnosis was confirmed. Treatment protocolĪll the patients were treated according to a study protocol based on approved international guidelines. Dactylitis was recorded as present or absent. The assessment for spinal involvement was carried out using ASDAS whereas nail assessment was carried out using Nail Psoriasis Severity Index (NAPSI). Enthesitis was assessed using the Maastricht Ankylosing Spondylitis Entheses Score (MASES).
Spss code elixhauser comorbid score skin#
Skin affection was assessed using both they included Body Surface Area (BSA), and Psoriasis Area and Severity Index (PASI). Score 4 - 14 - 28 reflect high disease activity. The total score is a simple sum of the scores. It encompasses 68 tender and 66 swollen joints count, scores for pain and patient global assessment a well as C-reactive protein level. Smoking status was defined.ĭisease Activity measures: Disease Activity for Psoriatic Arthritis (DAPSA) was used as composite measure to assess the PsA disease activity. Patients who missed 2 consecutive appointments, were excluded from the work and statistical analysis.īody mass index (BMI) was calculated from measures taken during the patient’s outpatient appointments and categorized per WHO criteria as ‘normal’, ‘overweight’ and ‘obese’. To minimize the potential of missing data, patients who missed their appointment were contacted a new follow up appointment was set up. This is a self- completed questionnaire evaluating the disease activity parameters, functional ability as well as quality of life. Prior to baseline examination in the clinic and every follow-up appointment, each patient completed a patient reported outcome measures (PROMs) questionnaire. Patients with past history of cancer or hepatitis, HIV or any other contraindication to DMARDs therapy. Patients taking oral steroids for non-arthritic/ other medical causes.ģ. Patients with history of RA, urogenital, intestinal or other forms of infection.Ģ. Results: PsA patients who had higher incidence of comorbid condition and were at high risk of hospitalization were men, with older age at disease onset, high BMI (p 6 weeks, or remittent pain involving any finger and/or toe for 3 months. Internal and external validation were carried out. A weighted index that was developed in a cohort of 1707 PsA patients. Outcomes of interest included functional ability, quality of life, medications induced complications, hospitalization/death. Methods: This was a retrospective multicenter cohort analysis of PsA patients in a rheumatology clinical registry, assessing the effect of different comorbidities measured at patients’ visits over 10-years period. 2.develop and validate a prospectively applicable comorbidity index for classifying PsA patients according to their comorbid conditions. identify comorbidities with greatest impact on PsA patients’ health status.
0 kommentar(er)
